Average Sales Price Reimbursement Not Affecting Roche Yet
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche has not seen any change in market dynamics for its products following the switch to an average sales price-based reimbursement model for Medicare Part B drugs
You may also be interested in...
Xeloda Growth Due To Off-Label Adjuvant Colorectal Cancer Use, Roche Says
The increase in Xeloda prescribing is also “partly due to some change in the reimbursement patterns,” Pharma Strategic Marketing Head Sabbah says. U.S. sales for the first quarter were up 74% to approximately $51 mil.
Xeloda Growth Due To Off-Label Adjuvant Colorectal Cancer Use, Roche Says
The increase in Xeloda prescribing is also “partly due to some change in the reimbursement patterns,” Pharma Strategic Marketing Head Sabbah says. U.S. sales for the first quarter were up 74% to approximately $51 mil.
Global Rx Market Will Grow 6%-7% In 2004, Roche Predicts
The company expects its own performance will surpass the market growth rate.